Author: Diego Moricoli

The AACR (American Association Cancer Research) recently concluded its IO (Immuno-Oncology) 2025 conference in Los Angeles, a four-day event (February 23-26) that brought together experts in the fields of cancer immunology and immunotherapy at the JW Marriott, Los Angeles.

The conference offered a comprehensive overview of this rapidly evolving field, from the basics of anti-tumor immune response to the latest clinical trials exploring new treatments. Topics addressed included the identification of T cells actively fighting the tumor, the challenges in producing cell therapies, and the spatial organization of immune cells in the tumor microenvironment.

Leading experts led symposia on highly relevant topics such as the personalization of therapies targeting neoantigens, the mechanisms of cancer resistance, the evasion of the immune response, and emerging discoveries in the biology of cancer immunotherapy.

Particular attention was given to monoclonal antibodies, with sessions dedicated to new strategies with multi-specific antibodies and antibody-drug conjugates. Other sessions explored the cutting-edge research areas, including the role of endogenous retroviruses in the immune response, the mechanisms behind T cell exhaustion in cancer treatment, the impact of the microbiome on the therapy responses and the development of oncolytic viruses and intratumoral immunotherapies.

The AACR IO 2025 served as an important meeting and updating opportunity for professionals in cancer immunology, offering a platform for knowledge sharing, collaboration, and definition of future directions for research and development in this field.

  • DIATHEVA is committed to advancing cutting-edge science. As a fully integrated company, we are active in research and development for novel monoclonal antibody therapeutics in the immune- oncology fields
  • In particular, the Anti-CEACAM1 antibody, a fully human recombinant antibody designed to act as an immune checkpoint inhibitor. By blocking CEACAM1, a protein often overexpressed in solid tumors, this antibody aims to enhance the body’s natural anti-tumor immune response. This therapy is currently in the preclinical phase of development.

Our portfolio of innovative therapeutics molecules includes also:

  • Anti-CD99 antibody that is currently in preclinical development and holds potential for treating Ewing’s sarcoma, acute lymphoblastic leukaemia, acute myeloid leukemia, and myelodysplastic syndromes.
  • A first-in-class humanized antibody against 1,3 beta-glucans, a key component of fungal cell walls. This anti-1,3 beta-glucans antibody is in discovery phase and offers a potential new treatment option for fungal infections.

Diego Moricoli, currently is Senior Bioprocess Scientist at Diatheva. Industrial Biotechnologist and PhD in Biochemistry and Pharmacology.